Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Apr 5;2:65.
doi: 10.3389/fmicb.2011.00065. eCollection 2011.

Pseudomonas Aeruginosa: Resistance to the Max

Affiliations
Free PMC article

Pseudomonas Aeruginosa: Resistance to the Max

Keith Poole. Front Microbiol. .
Free PMC article

Abstract

Pseudomonas aeruginosa is intrinsically resistant to a variety of antimicrobials and can develop resistance during anti-pseudomonal chemotherapy both of which compromise treatment of infections caused by this organism. Resistance to multiple classes of antimicrobials (multidrug resistance) in particular is increasingly common in P. aeruginosa, with a number of reports of pan-resistant isolates treatable with a single agent, colistin. Acquired resistance in this organism is multifactorial and attributable to chromosomal mutations and the acquisition of resistance genes via horizontal gene transfer. Mutational changes impacting resistance include upregulation of multidrug efflux systems to promote antimicrobial expulsion, derepression of ampC, AmpC alterations that expand the enzyme's substrate specificity (i.e., extended-spectrum AmpC), alterations to outer membrane permeability to limit antimicrobial entry and alterations to antimicrobial targets. Acquired mechanisms contributing to resistance in P. aeruginosa include β-lactamases, notably the extended-spectrum β-lactamases and the carbapenemases that hydrolyze most β-lactams, aminoglycoside-modifying enzymes, and 16S rRNA methylases that provide high-level pan-aminoglycoside resistance. The organism's propensity to grow in vivo as antimicrobial-tolerant biofilms and the occurrence of hypermutator strains that yield antimicrobial resistant mutants at higher frequency also compromise anti-pseudomonal chemotherapy. With limited therapeutic options and increasing resistance will the untreatable P. aeruginosa infection soon be upon us?

Keywords: Pseudomonas aeruginosa; antimicrobial; biofilm; efflux; hypermutability; resistance; β-lactamase.

Similar articles

See all similar articles

Cited by 210 articles

See all "Cited by" articles

References

    1. Abraham N., Kwon D. H. (2009). A single amino acid substitution in PmrB is associated with polymyxin B resistance in clinical isolate of Pseudomonas aeruginosa. FEMS Microbiol. Lett. 298, 249–254 - PubMed
    1. Akpaka P. E., Swanston W. H., Ihemere H. N., Correa A., Torres J. A., Tafur J. D., Montealegre M. C., Quinn J. P., Villegas M. V. (2009). Emergence of KPC-producing Pseudomonas aeruginosa in Trinidad and Tobago. J. Clin. Microbiol. 47, 2670–2671 - PMC - PubMed
    1. al Naiemi N., Duim B., Bart A. (2006). A CTX-M extended-spectrum β-lactamase in Pseudomonas aeruginosa and Stenotrophomonas maltophilia. J. Med. Microbiol. 55, 1607–1608 - PubMed
    1. Arora S., Bal M. (2005). AmpC β-lactamase producing bacterial isolates from Kolkata hospital. Indian J. Med. Res. 122, 224–233 - PubMed
    1. Aubert D., Poirel L., Chevalier J., Leotard S., Pages J. M., Nordmann P. (2001). Oxacillinase-mediated resistance to cefepime and susceptibility to ceftazidime in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 45, 1615–162010.1128/AAC.45.6.1615-1620.2001 - DOI - PMC - PubMed

LinkOut - more resources

Feedback